PEGASUS-TIMI 54 Long-term DAPT Benefit Index (PEGASUS DAPT Benefit Calculator)

Clinical calculation support · Verify results before clinical use

Patient characteristics

Enter clinical features to assess the PEGASUS-TIMI 54 trial phenotype.

PEGASUS-TIMI 54 enrolled patients aged 50 years or older.

Spontaneous myocardial infarction 1–3 years before assessment?

This is a core trial-population criterion; select Yes only when the qualifying MI timing and spontaneous nature are established.

Diabetes mellitus requiring medication

A documented diagnosis treated with medication.

Second prior spontaneous myocardial infarction

An additional prior spontaneous MI, separate from the qualifying event.

Multivessel coronary artery disease

Documented multivessel coronary disease.

The trial renal-risk feature was CrCl <60 mL/min. Use an appropriately calculated Cockcroft–Gault estimate.

Potential major bleeding / treatment exclusion concern?

Consider oral anticoagulation, recent GI bleeding, prior intracranial bleeding/stroke, bleeding disorders, and other trial exclusions. This single flag is not a complete bleeding-risk assessment.

How to interpret this assessment

PEGASUS-TIMI 54 studied stable patients aged 50 years or older with a spontaneous MI 1–3 years earlier and at least one additional high-risk feature: age ≥65 years, diabetes requiring medication, a second prior spontaneous MI, multivessel coronary disease, or Cockcroft–Gault CrCl <60 mL/min.

What the numbers mean

  • Eligibility phenotype: a checklist approximation of key trial entry features; it is not a treatment recommendation.
  • ARR: difference between the trial's 3-year placebo and ticagrelor 60 mg event estimates for CV death, MI, or stroke.
  • NNT: approximate number treated for the trial follow-up to prevent one primary efficacy event, based on the absolute difference.
  • Bleeding trade-off: TIMI major bleeding was more frequent with ticagrelor. Individual bleeding risk and contraindications require a separate assessment.

Clinical considerations

Before considering prolonged DAPT, assess ischemic risk, bleeding history, concomitant anticoagulants, prior stroke or intracranial bleeding, renal and hepatic status, drug tolerance/interactions, patient preferences, and current guideline recommendations. Do not use the trial-average ARR/NNT as a personalized prediction.

Evidence and references

Bonaca MP, et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine. 2015;372:1791–1800. Primary PEGASUS-TIMI 54 report. doi:10.1056/NEJMoa1500857; PMID: 25773268.
American College of Cardiology. PEGASUS-TIMI 54 Clinical Trial Summary. Trial design, inclusion/exclusion criteria, and principal outcomes. Official ACC trial summary.
Clinical disclaimer: This educational calculator summarizes selected PEGASUS-TIMI 54 trial characteristics and average outcomes. It is not a validated individualized benefit-risk model and does not replace clinician judgment, formal bleeding-risk assessment, current guidelines, local product information, or shared decision-making. Do not start, stop, or change antiplatelet therapy based on this tool alone.